公开(公告)号：EP3630283A1

公开(公告)日：2020-04-08

申请号：EP18810795.7

申请日：2018-05-31

申请人： Immunolight, LLC ,  Duke University

发明人： BOURKE, Frederic A. ,  DEWHIRST, Mark ,  SPECTOR, Neil ,  YOON, Paul ,  ADAMSON, Justus ,  ALCORTA, David ,  LYERLY, Kim ,  LIU, Leihua ,  OSADA, Takuya ,  OLDHAM, Mark ,  FATHI, Zakaryae ,  BEYER, Wayne F. ,  WALDER, Harold

IPC分类号： A61N5/06 ,  A61B6/00 ,  A61K9/00 ,  A61K49/04 ,  A61N5/10

公开(公告)号：EP3365017A1

公开(公告)日：2018-08-29

申请号：EP16858126.2

申请日：2016-10-19

申请人： Immunolight, LLC ,  Duke University

发明人： FATHI, Zakaryae ,  BAYER, Wayne, F. ,  WALDER, Harold ,  BOURKE, Frederic, A. ,  OLDHAM, Mark ,  DEWHIRST, Mark ,  SPECTOR, Neil, L. ,  YOON, Paul ,  ADAMSON, Justus ,  ALCORTA, David ,  LYERLY, Kim ,  LIU, Leihua ,  OSADA, Takuya

IPC分类号： A61K41/00

CPC分类号： A61K41/0057 ,  A61K33/42 ,  A61K41/0066 ,  A61N5/00 ,  A61N5/062 ,  A61N5/10 ,  A61N2005/1098

摘要： A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.

公开(公告)号：EP2788004A1

公开(公告)日：2014-10-15

申请号：EP12861144.9

申请日：2012-12-07

申请人： Duke University

发明人： KORNBLUTH, Sally ,  KUROKAWA, Manabu ,  SPECTOR, Neil ,  DEWHIRST, Mark

IPC分类号： A61K31/675 ,  A61K31/40 ,  A61K39/395 ,  G01N33/53

CPC分类号： A61K31/517 ,  A61K31/404 ,  A61K31/407 ,  A61K31/496 ,  A61K39/39558 ,  A61K45/06 ,  C07K16/32 ,  C12N15/1135 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/531 ,  C12Y603/02 ,  G01N33/5011 ,  G01N2800/52 ,  A61K2300/00

摘要： Methods of treating subjects with cancer and screening for MDM2 inhibitors that may be effective cancer therapeutics are provided herein. The cancers that may be treated using MDM2 inhibitors using the methods described herein include those that are or may become resistant to treatment with tyrosine kinase inhibitors. Methods of treating subjects with cancers that have, or develop in response to treatment with tyrosine kinase inhibitors, elevated levels of MDM2, Mcl-1 or PP5 or decreased levels of Huwe1 or CAS using MDM2 inhibitors are provided herein. The MDM2 inhibitors may be effective at treating these cancers alone or in combination with a tyrosine kinase inhibitor regardless of p53 status (mutant or wild-type) of the cancer.

公开(公告)号：EP3606614A1

公开(公告)日：2020-02-12

申请号：EP18781786.1

申请日：2018-04-04

申请人： Biomimetix JV LLC ,  Duke University

发明人： ASHCRAFT, Kathleen ,  DEWHIRST, Mark ,  BATINIC-HABERLE, Ines ,  CRAPO, James, D.

IPC分类号： A61P35/00 ,  C07D207/02

公开(公告)号：EP2788004B1

公开(公告)日：2019-07-03

申请号：EP12861144.9

申请日：2012-12-07

申请人： Duke University

发明人： KORNBLUTH, Sally ,  KUROKAWA, Manabu ,  SPECTOR, Neil ,  DEWHIRST, Mark

IPC分类号： A61K31/496 ,  A61K39/395 ,  G01N33/53 ,  A61K31/517 ,  A61K31/407 ,  A61P35/00 ,  G01N33/50 ,  C12N15/113 ,  C07K16/32 ,  A61K45/06